Liquidity & Technical
Liquidity & Technical
Molina Healthcare offers institutionally tradable liquidity for size-aware funds — a 5% position is implementable within a five-day execution window for funds up to roughly $3.5B at 20% ADV, but block-level discipline still matters at the $200M+ size tier. The tape itself is the more interesting tell: a brutal 12-month drawdown bottomed in spring 2025, and price has now climbed back above its 200-day average with a fresh 50/200 golden cross printed on 2026-06-02 — the single most important technical feature on the chart.
1 — Portfolio implementation verdict
5-Day Capacity (20% ADV)
Max Position in 5d (% mcap)
Fund AUM Supported (5% wt)
20d ADV / Mkt Cap
Technical Score (+3 / −3)
Liquidity is adequate for the typical mid-cap allocation, and the tape just turned constructive after a violent drawdown — but the bulk of the past 12 months traded under heavy-volume selling on negative news, and 1-year relative strength remains deeply negative. The setup is improving, not confirmed.
2 — Price snapshot
Current Price
YTD Return
1-Year Return
52-Week Position
30d Realized Vol
3 — Critical chart: 10-year price with 50/200 SMA
Price is above the 200-day SMA ($167.39) by 18.2%, and a fresh golden cross (50-day above 200-day) printed on 2026-06-02 — the third in three years, following two death crosses in 2024 and 2025. The 10-year chart frames a familiar managed-care cycle: a 2017–2021 secular uptrend from $50 to $300+, an all-time peak of $420 in late 2023, a 70%+ peak-to-trough drawdown into mid-2025, and a sharp V-shaped recovery now back above $200. This is an emerging-uptrend regime, with the recovery still incomplete.
4 — Relative strength (3-year rebased path)
Broad-market (SPY) and sector (XLV) benchmark series were not populated in the relative-performance file, so a side-by-side comparison cannot be rendered without fabricating data. The company-only path tells the same story: a 31% drawdown over three years against an SPY total return that was meaningfully positive over the same window. Relative strength versus the S&P 500 is firmly negative on a 3-year basis, and the stock has only just begun to claw back ground in the last two months.
5 — Momentum: RSI + MACD
RSI(14) sits at 62.0, climbing from the high-40s in March and the low-30s during the late-2025 capitulation — short of an overbought reading (70+) but firmly in bullish territory. The MACD histogram has flipped positive and is widening for the third straight week, with the signal line crossing under the MACD line in mid-May. Both indicators agree: near-term momentum is bullish but not yet stretched, leaving room for another 5–10% before overbought signals would warrant caution.
6 — Volume, volatility, and sponsorship
The top volume-spike days of the past 18 months are revealing — and they are all downside events:
Each of the three biggest-volume days in the past 18 months was a sharp DOWN day — distribution, not accumulation. The recovery since spring 2025 has come on more modest volume, which is a structural caveat: the tape rallies on lighter participation than the tape sells. Recent 50-day average volume is trending up alongside price, which is constructive — but the dominant tape signature of the past year was forced selling.
30-day realized volatility sits at 41.1% — above the 10-year p50 of 31.4% but below the p80 of 48.3%. Translation: elevated, not stressed. The market is still demanding a wider risk premium than normal, consistent with a stock that has just exited a 70%+ drawdown and is rebuilding investor confidence. A move back toward p20 (24.4%) would signal the recovery has been fully accepted.
7 — Institutional liquidity panel
A — ADV and turnover
ADV 20d (shares)
ADV 20d ($ value)
ADV 60d (shares)
ADV / Mkt Cap
Annual Turnover
B — Fund-capacity table
C — Liquidation runway
D — Daily-range proxy
Median 60-day daily range of 1.88% is mildly elevated for a $10B mid-cap — close to the 2% threshold where block-execution friction starts to bite for orders above $50M. A patient VWAP/POV strategy is appropriate at the larger size tiers; market-on-open or aggressive lit liquidity will leak basis points.
A 0.5%-of-market-cap position ($52M) clears the 5-day threshold comfortably at 10% participation; a 1%-of-mcap position ($105M) clears at 20% participation but requires nearly two trading weeks at 10%. Above 1% of mcap, this becomes a multi-week build/exit problem — not unimplementable, but no longer a "click-buy" name.
8 — Technical scorecard and stance
Net technical score: +1 of a possible +6 — mildly constructive, anchored by trend and momentum but offset by a poor relative-strength track record and volume conviction that has not yet rotated decisively to the buy side.
Stance — neutral-to-bullish on the 3-to-6 month horizon
The recovery off the May 2025 low is real, the 200-day reclaim is durable, and the golden cross gives trend-followers permission to participate. But the tape spent most of the past year being sold, not bought, on every catalyst — that history does not flush in eight weeks. We are constructive on a 3-to-6-month timeframe with the following invalidation rails:
- Above $215 (52-week midpoint, prior congestion zone): confirms the breakout, opens a path back to the $240–260 zone where the next overhead supply sits.
- Below $172 (50-day SMA / recent breakout floor): invalidates the recovery, signals the golden cross is failing, and re-opens the path to retest the $122 52-week low.
Liquidity is not the constraint for funds operating below the $3.5B AUM threshold at a 5% position weight. For funds above that scale or running 1%+ of market cap as a single name, build the position over several weeks using participation-disciplined execution rather than treating it as a single-day trade. The technical setup justifies a starter position or watchlist entry; the high-conviction add comes on either a clean reclaim of $215 or a confirmed re-test of the 200-day that holds.